Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23419126)

1.

Influence of bosentan on fingertip rewarming in patients with systemic sclerosis.

Autenrieth J, Riemekasten G, Bert C, Worm M.

J Dtsch Dermatol Ges. 2013 Apr;11(4):356-9. doi: 10.1111/ddg.12058. Epub 2013 Feb 19. No abstract available.

PMID:
23419126
2.

Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.

Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F.

J Rheumatol. 2010 Dec;37(12):2531-9. doi: 10.3899/jrheum.100358. Epub 2010 Sep 1.

PMID:
20810512
3.
4.
5.

Effects of bosentan on the skin lesions: an observational study from a single center in Japan.

Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, Kinoshita K.

Rheumatol Int. 2009 May;29(7):769-75. doi: 10.1007/s00296-008-0789-z. Epub 2008 Nov 27.

PMID:
19037604
6.

Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.

Hettema ME, Zhang D, Bootsma H, Kallenberg CG.

Ann Rheum Dis. 2007 Oct;66(10):1398-9. No abstract available.

7.

Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.

Nishibu A, Sakai E, Oyama N, Yamamoto T.

Australas J Dermatol. 2012 May;53(2):e32-3. doi: 10.1111/j.1440-0960.2010.00719.x. Epub 2010 Nov 29.

PMID:
22571581
8.

Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.

Moore TL, Vail A, Herrick AL.

Rheumatology (Oxford). 2007 Feb;46(2):363-4. Epub 2006 Nov 20. No abstract available.

9.

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C.

Arthritis Rheum. 2004 Dec;50(12):3985-93.

10.

A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.

Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G, Mahamid H, Bambara LM, Biasi D.

Clin Rheumatol. 2009 Jul;28(7):807-13. doi: 10.1007/s10067-009-1155-6. Epub 2009 Mar 20.

PMID:
19301062
11.

Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis.

Dunne J, Dutz J, Shojania K, Ng B, van Eeden S.

Rheumatology (Oxford). 2006 Jul;45(7):911-2. Epub 2006 Mar 10. No abstract available.

12.

Digital ulcers: overt vascular disease in systemic sclerosis.

Steen V, Denton CP, Pope JE, Matucci-Cerinic M.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii19-24. doi: 10.1093/rheumatology/kep105. Review.

13.

Infrared functional imaging applied to Raynaud's phenomenon.

Merla A, Di Donato L, Di Luzio S, Farina G, Pisarri S, Proietti M, Salsano F, Romani GL.

IEEE Eng Med Biol Mag. 2002 Nov-Dec;21(6):73-9. No abstract available.

PMID:
12613214
14.

Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.

Tsifetaki N, Botzoris V, Alamanos Y, Argyriou E, Zioga A, Drosos AA.

J Rheumatol. 2009 Jul;36(7):1550-2. doi: 10.3899/jrheum.080992. No abstract available.

PMID:
19567637
15.

Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.

Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.

J Rheumatol. 2008 Sep;35(9):1830-7. Epub 2008 Jul 15.

PMID:
18634152
16.
17.
18.

Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.

Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S.

Mod Rheumatol. 2012 Feb;22(1):94-9. doi: 10.1007/s10165-011-0472-1. Epub 2011 Jun 3.

PMID:
21633912
19.

[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].

Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O, Jego P, Carpentier P, Hatron PY, Hachulla E.

Presse Med. 2006 Apr;35(4 Pt 1):587-92. French.

20.

Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.

Ramos-Casals M, Brito-Zerón P, Nardi N, Claver G, Risco G, Parraga FD, Fernandez S, Julià M, Font J.

Rheumatology (Oxford). 2004 Nov;43(11):1454-6. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk